QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Gaining New Recognition For Its Work With Parkinson's 0 comments
    Oct 23, 2013 1:58 PM | about stocks: ISCO

    When Agora Financial issued one of their Breakthrough Technology Alerts, it called ISCO stock "dirt-cheap at today's prices, considering the technology it owns and the potential it could unlock." ISCO's October presentation at the American Neurological Association's (ANA) 2013 annual meeting clarified some of that potential.

    International Stem Cell Corp. is the developer of a revolutionary stem cell generation process called parthenogenesis, which avoids the controversial use of human embryos while at the same time greatly reducing the immune matching problems often associated with the use of donor stem cells. They are now showing the world some of the ways this dramatic new technology can be applied through their various therapeutic research programs, the primary one being the use of parthenogenesis for the generation of neural stem cells, research focused on the treatment of Parkinson's disease.

    Progress on ISCO's Parkinson's program was released in their recent presentation before the ANA, where Dr. R. Semechkin, ISCO's Chief Scientific Officer, explained how their test results have now established a solid foundation for the clinical use of neural stem cells for the treatment of Parkinson's, and also for the potential treatment of other neurological diseases, such as Alzheimer's. ISCO research and tests show that their neural stem cells are able, after implantation, to effectively travel to the correct place in the brain, where they change into the type of neurons lost through the disease. In addition, they elicited a lower immunogenic response compared with other cell types.

    ISCO is also actively engaged in work for the application of their stem cells to liver disease and the development of human corneas needed around the world for corneal transplants. Regarding the Parkinson's program, the Agora Financial article emphasized that "The initiation of a Phase 1 trial in humans, and especially good data from that trial, will raise ISCO's profile considerably. The trials are expected to begin in the middle of 2014."

    For additional information, visit InternationalStemCell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.